rly-4008
relay therapeutics
['rly-4008', 'fgfr2 inhibitor']
 exciting news! hot off the press with a simultaneous publication in cancer discovery with the #asco23 clinical science symposium meeting so honored to present to the world rly-4008 - the first highly selective fgfr2 inhibitor with activity across 
Chief, Early-Phase Drug Development|@SarahCannonDocs
#Oncologist, #Phase1trials, #PrecisionMedicine. Tweets=My own.